Imidazenil
Imidazobenzodiazepine anxiolytic, GABA-A partial agonist, preclinical data only.
Pharmacology
Contents
WHAT IS IMIDAZENIL?
Detailed overview
Imidazenil is an imidazobenzodiazepine anxiolytic that acts as a partial positive allosteric modulator at the benzodiazepine binding site of the GABA-A receptor, meaning it has lower intrinsic efficacy than full benzodiazepines. It shows subunit selectivity: weak activity at alpha1-containing receptors and fuller agonism at alpha5-containing receptors, which may explain why it is markedly less sedating than diazepam in animal studies while remaining anticonvulsant and anxiolytic. In preclinical models it produced anticonvulsant, neuroprotective and pro-social effects without the development of tolerance. There are no human clinical trials: the compound has never been approved or marketed for human use and remains a laboratory research tool.
Mechanism
GABA-A benzodiazepine-site partial agonist
Evidence
Preclinical only (no human data)
Legal status
Unapproved research compound
Receptor profile
- Benzodiazepine site (GABA-A)Strong
- GABA-A alpha5 subunit (fuller agonism)Strong
- GABA-A alpha1 subunit (weak, low sedation)Weak
- Tolerance / dependence liabilityModerate
Safety
Side effects, stop signs, contraindications
Side effects · 5
- No human safety data: only preclinical (rodent and guinea pig) studies exist; the compound has never been registered in humans
- Reduction of locomotor activity at higher doses
- Benzodiazepine class effects (sedation, incoordination) cannot be excluded in principle, though much milder than diazepam in animals
- As a partial agonist, unknown human tolerance and withdrawal profile
- Unknown long-term safety and incomplete toxicology profile in humans
Contraindications · 4
- Pregnancy and breastfeeding: safety not established, avoid
- Other CNS depressants (alcohol, opioids, other benzodiazepines): theoretical risk of additive effects
- Benzodiazepine hypersensitivity or prior substance-use disorder
- Not an approved medicine; experimental research compound, not recommended without clinical supervision
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
Imidazenil, a non-sedating anticonvulsant benzodiazepine, is more potent than diazepam in protecting against DFP-induced seizures and neuronal damage
Kadriu B, Guidotti A, Costa E, Auta J
Acute imidazenil treatment after the onset of DFP-induced seizure is more effective and longer lasting than midazolam at preventing seizure activity and brain neuropathology
Kadriu B, Guidotti A, Costa E, Davis JM, Auta J
Absence of tolerance to the anticonvulsant and neuroprotective effects of imidazenil against DFP-induced seizure and neuronal damage
Kadriu B, Gocel J, Larson J, Guidotti A, Davis JM, Costa E, Auta J
Neuroprotective effects of imidazenil against chemical warfare nerve agent soman toxicity in guinea pigs
Wang Y, Weiss MT, Yin J, Frew R, Tenn CC, Nelson PP, Vair C, Sawyer TW, Mikler J
Imidazenil and diazepam increase locomotor activity in mice exposed to protracted social isolation
Pinna G, Agis-Balboa RC, Zhubi A, Matsumoto K, Grayson DR, Costa E, Guidotti A
FAQ
FAQ
Imidazobenzodiazepine anxiolytic, GABA-A partial agonist, preclinical data only.
Telegram
Have a question about Imidazenil?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.